February 21, 2019 / 2:27 PM / a month ago

Catalyst defends drug price after Bernie Sanders' rebuke

Feb 21 (Reuters) - Catalyst Pharmaceuticals Inc, targeted by U.S. Senator Bernie Sanders for high drug prices, said on Thursday that prices of its treatment for a rare neurological disorder were "in line" with similar products in the industry.

Sanders this month wrote to the Florida-based drugmaker asking it to justify its $375,000-per-year price for Firdapse, a medication that for years has been available for free.

Catalyst also said it spends "millions of dollars per year" evaluating Firdapse in clinical trials testing it in other diseases. (bit.ly/2NkmIRU) (Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin Ravikumar)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below